Trial Profile
Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Takayasu syndrome
- Focus Therapeutic Use
- 16 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism